The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

M. Black, Dennis; R. Reid, Ian; A. Cauley, Jane; Cosman, Felicia; Leung, Ping‐Chung; Lakatos, Péter; Lippuner, Kurt; R. Cummings, Steven; F. Hue, Trisha; Mukhopadhyay, Amitava; Tan, Monique; Paul Aftring, R.; Eastell, Richard

doi:10.1002/jbmr.2442

Public

The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)

Published in Journal of Bone and Mineral Research • Dec 26, 2014

Authors:

Dennis M. Black

Ian R. Reid

Jane A. Cauley

Abstract

ABSTRACT While bisphosphonates reduce fracture risk over 3 to 5 years, the optimal duration of treatment is uncertain. In a randomized extension study (E1) of the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly−Pivotal Fracture Trial (HORIZON−PFT), zoledronic acid (ZOL) 5 mg a...

Subject

Medicine

Zoledronic acid

Discontinuation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!